Non-alcoholic fatty liver disease (NAFLD) is currently the world's most common liver
disease, estimated to affect up to one-fourth of the population. Hallmarked by hepatic …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

Alcohol abuse is the most common cause of fatty liver disease, but it is now apparent that fat
deposition in the liver, and its consequences, may occur without alcohol abuse. The …

Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic
syndrome. It represents a wide spectrum of histopathological abnormalities ranging from …

Nonalcoholic steatohepatitis (NASH), the lynchpin between steatosis and cirrhosis in the
spectrum of nonalcoholic fatty liver disorders (NAFLD), was barely recognized in 1981 …

Background and Aims: The pathogenesis of nonalcoholic steatohepatitis (NASH) is
unknown. We tested the hypothesis that NASH is associated with 2 defects:(1) peripheral …

Drugs are typically small molecules that are generally classified as xenobiotics, which are
foreign to the human body. Several endogenous molecules, however, such as steroids and …

Drug-induced hepatic injury accounts for more than 50 percent of cases of acute liver failure
in the United States. More than 75 percent of idiosyncratic drug reactions result in liver …

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from
hepatocellular steatosis through steatohepatitis to fibrosis and irreversible cirrhosis. The …

Nonalcoholic steatohepatitis (NASH) is often linked with disorders that are clearly
associated with insulin resistance (IR): obesity, type 2 diabetes mellitus, and …